COMMUNIQUÉS West-GlobeNewswire

CV Sciences, Inc. Announces Landmark Publication on the Toxicology and Safety Assessment of Base Material of its PlusCBD Oil™ Products
15/06/2018
LAS VEGAS, June 15, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our” or “we”) announced today the June 7, 2018 publication of the toxicology and safety results of an extract [...]
Medtronic Receives FDA Approval for 200mm & 250mm IN.PACT(TM) Admiral(TM) Drug Coated Balloons
15/06/2018
New, Extended Balloon Lengths Enable Physicians to Efficiently Treat Long SFA Lesions DUBLIN - June 15, 2018 - Medtronic plc (NYSE: MDT) today announced that it has received U.S. Food and Drug Administration (FDA) [...]
Stemline Therapeutics Announces Presentation of ELZONRIS™ (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress
15/06/2018
NEW YORK, June 15, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that ELZONRIS™ (tagraxofusp; SL- [...]
TG Therapeutics, Inc. Announces Oral Presentation of Umbralisib plus Ruxolitinib in Patients with Myelofibrosis at the 23rd Congress of the European Hematology Association
15/06/2018
Data demonstrates that the addition of umbralisib to ruxolitinib can induce responses in patients with sub-optimal response to ruxolitinib single agent NEW YORK, June 15, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ( [...]
Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association
15/06/2018
NEW YORK and LONDON, June 15, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan [...]
Insmed Announces FDA Advisory Committee Meeting to Review ALIS as a treatment for NTM Lung Disease Caused by MAC
15/06/2018
Meeting planned for August 7, 2018 BRIDGEWATER, N.J., June 15, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, [...]
Extendicare Announces June 2018 Dividend of C$0.04 per Share
15/06/2018
MARKHAM, Ontario, June 15, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share [...]
Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association
15/06/2018
CG-806 Continues to Demonstrate Superior Activity to Ibrutinib BTK Inhibitor STOCKHOLM, Sweden and SAN DIEGO, June 15, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the [...]
Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study
15/06/2018
Study completion and submission of 510(k) notification expected in Calendar Q3 2018 FRAMINGHAM, Mass., June 15, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of [...]
Summit Therapeutics to Present at the JMP Securities Life Sciences Conference
15/06/2018
Summit Therapeutics plc ("Summit", or the "Company") Summit Therapeutics to Present at the JMP Securities Life Sciences Conference Oxford, UK, and Cambridge, MA, US, 15 June 2018 - Summit Therapeutics plc (NASDAQ: SMMT [...]
AMAG Pharmaceuticals Announces Divestiture of Cord Blood Registry®
15/06/2018
Transaction Underscores AMAG’s Focus on Clinical Development and Commercialization of Pharmaceuticals Company Intends to Use the Majority of Proceeds to Pay off High-Yield Debt WALTHAM, Mass., June 15, 2018 (GLOBE [...]
Aclaris Therapeutics Expands Leadership Team, Appointing Dr. David Gordon as Chief Medical Officer
15/06/2018
Former Deputy Office Director at the FDA, Elaine Morefield, PhD, also joins Aclaris WAYNE, Pa., June 15, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company [...]
Summit Therapeutics to Present at the JMP Securities Life Sciences Conference
15/06/2018
Oxford, June 15, 2018 (GLOBE NEWSWIRE) -- Oxford, UK, and Cambridge, MA, US, 15 June 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Glyn Edwards, Chief Executive Officer, will present at the JMP [...]
Athenex Announces Appointment to Board of Directors
15/06/2018
BUFFALO, N.Y., June 15, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Trillium Therapeutics Completes Amendment to SIRPaFc License Agreement
15/06/2018
Trillium to issue C$3 million of common shares to retire sublicense revenue sharing provision TORONTO, June 15, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno- [...]
PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company
15/06/2018
Oslo (Norway), 15 June 2018 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company [...]
Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Association (EHA)
15/06/2018
Consistently High Responses in Patients with an EZH2 Activating Mutation Durable Clinical Responses and Progression-Free Survival Observed in Patients With or Without an EZH2 Activating Mutation Company to Host Investor [...]
Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
15/06/2018
3-month Phase 2 data continue to show SEL-212 (SVP-Rapamycin + pegsiticase) may present a superior product profile over current FDA-approved chronic severe gout therapy with serum uric acid (SUA) control of 81%, reduced [...]
Affimed Announces Updated Data of AFM13 in Combination with Keytruda® (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA
15/06/2018
Best response data from 18 patients confirms favorable safety profile and overall response rate of 89% Management to host conference call today at 8:30 a.m. ET / 2:30 p.m. CET to discuss future development plans for [...]

Pages